Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mutations of the BRAF oncogene occur in both melanomas and several other cancers. Our objective was to determine if mutant BRAF V600E expression in a population-based cohort of patients with melanoma was associated with the development of a second primary malignancy of any type. Using the resources of the Rochester Epidemiology Project, we retrospectively identified 380 patients aged 18 to 60 years who were diagnosed with an incident melanoma from 1970 through 2009. We reviewed individual medical records to identify second primary malignancies. We evaluated mutant BRAF V600E expression from available melanoma tissue specimens and assessed its association with the development of a second primary malignancy. BRAF V600E expression in melanomas is associated with an increased risk for basal cell carcinoma (BCC).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12788/cutis.0607 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A compilation of 13 patients with metastatic colorectal cancer and concomitant and family mutations.
Front Oncol
August 2025
Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
Introduction: Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 () and rat sarcoma () family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant and mutations, posing unique challenges and implications for clinical management.
View Article and Find Full Text PDFEpithelioid glioblastoma mimicking metastatic brain tumor: A case report and literature review.
Radiol Case Rep
November 2025
Department of Neurosurgery, Hitachi General Hospital, 2-1-1 Jonancho, Hitachi 317-0077, Japan.
Epithelioid glioblastoma (eGBM) is a rare subtype of glioblastoma, generally associated with a poorer prognosis than conventional GBM despite maximum resection and standard chemoradiotherapy. Here, we report a case of a 78-year-old man who presented with left hemiplegia and a well-circumscribed right frontal lobe lesion on imaging, initially suspected to be a metastatic brain tumor. Surgical resection revealed a firm, clearly demarcated mass.
View Article and Find Full Text PDF[Glomangiomatosis of uncertain malignant potential: a clinicopathological and genetic analysis].
Zhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.
To investigate the clinicopathological features, genetic characteristics, and differential diagnosis of glomangiomatosis with uncertain malignant potential. Two cases of glomangiomatosis with uncertain malignant potential were collected at Henan Provincial People's Hospital from 2013 and 2023. Immunohistochemistry and next generation sequencing (DNA-seq) were used to detect the related protein and gene variation.
View Article and Find Full Text PDFUltrasensitive multifunctional biosensor integrating ECL quenching and DPV enhancement for early classification of thyroid cancer via BRAF V600E and microRNA-221 detection.
Biosens Bioelectron
September 2025
College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun, 130012, China. Electronic address:
Papillary thyroid carcinoma (PTC) is the most prevalent form of thyroid cancer with a high incidence among endocrine malignancies. It tends to metastasize early in lymph nodes and differs markedly from other subtypes in biological behavior, clinical management, and prognosis. Therefore, accurately distinguishing PTC from other pathological subtypes is crucial for guiding diagnosis and treatment decisions.
View Article and Find Full Text PDFMultimodal ultrasonographic and clinicopathological model for predicting high-volume lymph node metastasis in cN0 papillary thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Medical Ultrasound, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Background: Given the challenge in preoperative diagnosis of high-volume lymph node metastasis (HVLNM) in clinical practice, we constructed and externally validated a comprehensive predictive model that integrated conventional ultrasound characteristics, contrast-enhanced ultrasound (CEUS) parameters, BRAFmutation, and clinicopathological data for HVLNM in clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).
Methods: Totally, 126 clinically lymph node-negative (cN0) PTC patients who underwent subtotal or total thyroidectomy and accompanied with prophylactic cervical lymph node dissection between December 2022 and December 2024 were enrolled in this retrospective study, and an additional 47 cN0 PTC patients included for the external validation cohort. Univariate and multivariate analysis were performed to identify the independent risk factors for HVLNM, and a binary logistic regression equation and relevant nomogram was constructed to predict the risk about HVLNM.